staurosporine has been researched along with tandutinib in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (69.23) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Giese, NA; Hollenbach, SJ; Hutchaleelaha, A; Lambing, JL; Pandey, A; Rose, JW; Scarborough, RM; Seroogy, JM; Volkots, DL; Yu, JC | 1 |
| Atteridge, CE; Azimioara, MD; Benedetti, MG; Biggs, WH; Carter, TA; Ciceri, P; Edeen, PT; Fabian, MA; Floyd, M; Ford, JM; Galvin, M; Gerlach, JL; Grotzfeld, RM; Herrgard, S; Insko, DE; Insko, MA; Lai, AG; Lélias, JM; Lockhart, DJ; Mehta, SA; Milanov, ZV; Patel, HK; Treiber, DK; Velasco, AM; Wodicka, LM; Zarrinkar, PP | 1 |
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Russu, WA; Shallal, HM | 1 |
| Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Chen, Z; Li, H; Lyu, J; Song, W; Sun, D; Xu, Y; Yang, Y; Zhao, Z; Zhou, W | 1 |
| Kiyoi, H | 4 |
| Ehninger, G; Illmer, T | 1 |
| Gary Gilliland, D; Tam, WF | 1 |
| Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
5 review(s) available for staurosporine and tandutinib
| Article | Year |
|---|---|
[Possibility of targeting FLT3 kinase for the treatment of leukemia].
Topics: Animals; Antibodies, Monoclonal; Benzoquinones; Carbazoles; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Lactams, Macrocyclic; Leukemia; Mutation; Piperazines; Pyrroles; Quinazolines; Quinones; Rifabutin; Staurosporine; Sunitinib | 2005 |
[Novel molecularly target therapies for leukemia].
Topics: Antineoplastic Agents; Carbazoles; Farnesyltranstransferase; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia; Piperazines; Quinazolines; Staurosporine | 2007 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
Can FLT3 inhibitors overcome resistance in AML?
Topics: Antineoplastic Agents; Carbazoles; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Piperazines; Quinazolines; Staurosporine | 2008 |
[FLT3 kinase inhibitors for the treatment of acute leukemia].
Topics: Acute Disease; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia; Mutation; Piperazines; Quinazolines; Signal Transduction; Staurosporine | 2010 |
8 other study(ies) available for staurosporine and tandutinib
| Article | Year |
|---|---|
Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family.
Topics: Administration, Oral; Animals; Biological Availability; Dogs; Enzyme Inhibitors; Female; fms-Like Tyrosine Kinase 3; Humans; In Vitro Techniques; Leukemia, Experimental; Leukemia, Myelomonocytic, Chronic; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Mutation; Phosphorylation; Piperazines; Plasma; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Quinazolines; Rats; Rats, Inbred Lew; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Structure-Activity Relationship; Tumor Cells, Cultured | 2002 |
A small molecule-kinase interaction map for clinical kinase inhibitors.
Topics: Benzamides; Drug Design; Escherichia coli; Escherichia coli Proteins; Imatinib Mesylate; Microchemistry; Pharmaceutical Preparations; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Pyrimidines | 2005 |
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comprehensive analysis of kinase inhibitor selectivity.
Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity | 2011 |
Discovery and Rational Design of Pteridin-7(8H)-one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Mutation; Phosphorylation; Protein Kinase Inhibitors; Pteridines | 2016 |
[The present status of, and problems with the development of FLT3 kinase inhibitors].
Topics: Adult; Cell Cycle Proteins; Chaperonins; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia; Leukemia, Promyelocytic, Acute; Mutation; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Staurosporine | 2006 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |